

Highlights



- A world-class, advanced four-product pipeline for >60 million US women
- Two Phase III-ready assets (confirmed by the FDA); **two likely blockbusters**
- 16 US and EU patents from a co-inventor of the best-selling US oral contraceptive
- A highly experienced management team with impressive accomplishments in women's health
- Raising a pre-IPO bridging round: \$1M for 8% of the public company
- Profitable exit options for investors

A Likely IPO (~1 year)
ROI Target: 8-10x

EXIT (3.5 - 4 years)
ROI Target: 30-40x



First-to-market, transformational products for critical unmet needs




<p>NUVOCEPT™ <i>Phase III-ready</i></p>	<p>The first and only oral contraceptive designed for women with high BMI (~ 20 million US women; >50% of the market); projected sales - \$1-2B/year.</p>
<p>PREMRING™ <i>Phase IIb asset</i></p>	<p>First-in-category medicated vaginal ring for uterine fibroids and endometriosis (~ 14 million US women). Optimal use of the best class of drugs; >\$1B/year.</p>
<p>ENHANTA™ <i>Phase IIb asset</i></p>	<p>First-in-category single non-hormonal therapy for painful, heavy menstrual periods (~ 25 million US women). Potential first-line for a prevalent disorder.</p>
<p>DUACEPT™ <i>Phase III-ready</i></p>	<p>The first oral contraceptive designed for women with cardiovascular risk factors. The safest option for normal-weight pill users. (~ 3 million US women).</p>

Executive Leadership



Arkady Rubin, PhD,
Founder, President/CSO

- Industry veteran (J&J, Pfizer) who contributed to the development and approval of top women's health products
- Co-inventor* of Ortho Tri-Cyclen Lo®, one of the best US oral contraceptives (\$1.8B/year in current market conditions).




Jon Stelzmler,
Acting CEO

- Four decades of impressive achievements in women's health.
- Career highlights: President of US Specialty Business (Lupin); Senior VP & General Manager of a \$1B Women's Healthcare Franchise (Bayer); Vice President (Pfizer)

We are seeking senior executives, advisors, and Board members.

Strategic Roadmap and Objectives



The Ask and Action Plan



Arstat is raising \$1M (bridge financing) ahead of a planned IPO

**\$10M Valuation Cap
(Post-Money)**

**The investors of this round are expected
to own 8% of the public company**

Major Tasks and Next Steps

- Finalize the senior executive team and assemble a well-connected board of directors
- Prepare the IND for NUVOCEPT/DUACEPT, identify the CRO for a Phase III study
- Arrange two more meetings with the FDA (ENHANTA and PREMRING)
- Conduct IPO-readiness activities and expand outreach to potential strategic partners
- **An IPO Underwriting Agreement (around Q4 of 2025)**
- **\$30-50M IPO at a targeted IPO valuation of \$120-150M (around Q2 of 2026)**

Please visit: www.arstatinfo.com **or Contact:** Arkady Rubin, PhD, President / CSO
E-mail: arubin@arstatinc.com
Tel: (347)385-0878